TransCode Therapeutics, Inc.
RNAZ
$1.78
-$0.11-5.82%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -74.13% | -58.19% | -106.87% | -81.78% | -37.39% |
| Total Depreciation and Amortization | -69.08% | -80.45% | -78.65% | -65.17% | -44.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.36% | 29.03% | 364.04% | 540.95% | 471.34% |
| Change in Net Operating Assets | 346.28% | 2,091.45% | 104.44% | 118.59% | -1,140.10% |
| Cash from Operations | -57.53% | -71.24% | -46.34% | 8.41% | 7.10% |
| Capital Expenditure | 50.00% | 62.78% | 69.27% | 97.65% | -3.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 67.16% | 75.56% | 79.82% | 97.65% | -3.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -46.01% | 54.77% | 21.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 28.48% | 18.26% | 92.20% | 50.34% | 20.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.91% | -80.97% | 294.37% | 117.22% | 1,945.87% |